Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc (GSK) reports on the vesting of conditional share awards under the 2009 Performance Share Plan and the 2009 Deferred Annual Bonus Plan. The reporting period covers the three-year performance measurement window from January 1, 2012, to December 31, 2014, with vesting transactions occurring on February 12, 2015, and March 9-12, 2015.
Key Financial Metrics and Performance Results
The filing details the performance outcomes against specific metrics for the 2012 awards. The filing text does not provide absolute revenue, profit, or cash flow figures for the period, but reports the following performance results:
- Adjusted Free Cash Flow: The company did not meet the threshold level of performance; this 25% element of the award lapsed in full.
- Total Shareholder Return (TSR): GSK ranked 10th (below median) against a comparator group of 10 global pharmaceutical companies; this 25% element lapsed in full.
- R&D New Products Sales: The company achieved sales above the threshold; 27% of this 25% element vested (6.75% of total award).
- Business Diversification: Sales in Vaccines, Consumer Healthcare, Dermatology, and Emerging Markets Asia Pacific and Japan were above threshold; 27% of this 25% element vested (6.75% of total award).
- Total Vesting Rate: 13.5% of the total 2012 Performance Share Plan awards vested.
Share Prices at Vesting (Feb 12, 2015): Ordinary Share: £14.855; ADS: US$45.95.
Material Changes and Award Outcomes
The primary material change reported is the significant lapse of executive compensation due to underperformance in cash flow and shareholder return metrics.
- Executive Directors: Sir Andrew Witty and other executives received vested shares/options representing 13.5% of their 2012 awards. For example, Sir Andrew Witty vested 59,660 Ordinary Shares and 49,575 Nil Cost Options, while the majority of his awards lapsed.
- Senior Executives (PDMRs): Awards granted to senior executives designated as Persons Discharging Managerial Responsibility (PDMRs) were based on EPS and operational/TSR targets. The filing indicates that for Mr. R Connor, Mrs. V Whyte, and Mr. N Hirons, 0% of their awards vested, with all awards lapsing.
- Deferred Bonus Plan: Matching shares for the Deferred Annual Bonus Plan followed the same 13.5% vesting rate as the Performance Share Plan.
Guidance, Risks, and Unusual Items
The filing does not contain forward-looking guidance, management commentary on future strategy, or specific risk factors beyond the disclosed performance failures.
- Unusual Items: The complete lapse of the Free Cash Flow and TSR components of the executive compensation plan represents a significant deviation from full vesting expectations.
- Contingencies: Dividends reinvested since the date of grant are not included in the current vesting figures and will be subject to a later announcement once final numbers are determined.
- Holding Tranche: 25% of Sir Andrew Witty's vested shares (14,915 ordinary shares) will be held back for an additional two years as agreed with shareholders.
Investor Verification Checklist
- Verify the specific adjusted free cash flow figures for the 2012-2014 period to understand the magnitude of the threshold miss.
- Confirm the composition of the 10-company comparator group used for the TSR ranking.
- Review the upcoming announcement regarding the final number of dividend shares to be reinvested for the vested awards.
- Check the exercise dates for the nil-cost options (valid until March 9, 2022).
- Monitor the "holding tranche" status for Sir Andrew Witty's shares over the next two years.